Apatinib can simultaneously suppress the kinase activities of VEGFR-2, c-Kit, and c-Src and is approved by the CFDA for the treatment of advanced gastric cancer (GC) in October 2014 [71, 72]. The gene discussed is KDR; the disease is gastric cancer.